Testosterone and diabetes: 10-year clinical, real-life data from a registry


Professor Saad presents 2017 data from a registry that started 2004 in a urological practice. Most patients were obese and approximately one third had type 2 diabetes. Treatment with testosterone undecanoate for 10 years reduced HbA1c from 9% to 6%, while in the non-treated control group HbA1c rose from 7.8% to 10.6%. Fasting insulin dropped from 30 to 14 µU/mL in the testosterone treated men, while it rose from 26 to 37 µU/mL in the non-treated control group. HOMA-IR followed a similar pattern, in the testosterone treated men it dropped from 10 to 3.8, while in the non-treated group it increased from 7.5 to 17. Among testosterone treated men, 81% achieved the HbA1c target of 6.5% and 91% achieved the HbA1c target of 7.0%. Notably, after 10 years of testosterone treatment 12% of men in the testosterone treated group were in remission, meaning that they don’t need any of their previous diabetes medications to stay below HbA1c of 6.5%. None of the patients in the non-treated group achieved the HbA1c targets. Weight loss in the testosterone groups was 20.2%, while weight gain in the non-treated group was 4.6%. In the testosterone group, there were 8 deaths (5.6%) – none due to cardiovascular events – while in the non-treated group there were 41 deaths (24.1%). There was no major cardiovascular event in the testosterone treated group. In contrast, in the non-treated group there were 47 (27.6%) myocardial infarctions and 37 (21.8%) stroke events. Prostate cancer was also lower in the testosterone treated group, 7 patients (5%) vs. 17 (10%) patients in the non-treated group. These data clearly show that long-term testosterone therapy is critical for improvement of type 2 diabetes and achievement of health benefits.



Prof. Dr. med. Marija Pfeifer

Farid Saad, PhD
Medical Affairs Andrology, Bayer AG, Berlin, Germany
Gulf Medical University School of Medicine, Ajman, UAE


  • Groti K, Zuran I, Antonic B, Forsnaric L, Pfeifer M. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. The aging male : the official journal of the International Society for the Study of the Aging Male. 2018;21(3):158-169. Return to content